Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 20 Issue 1, January 2021

Target assessment, inspired by the Perspective on p64.

Cover design: Susanne Harris.

Comment

  • Greater investment is needed in antibiotic R&D, and more must be done to maximize the impact of such investments. More widespread data sharing, such as the recent joint data contribution from Merck and Kyorin to the Pew Charitable Trusts’ SPARK platform, has a key role.

    • Wes Kim
    • Kevin Krause
    • Kevin Outterson
    Comment

    Advertisement

Top of page ⤴

News & Analysis

  • Exosomes — small extracellular vesicles that are shed by cells — have long offered promise as drug delivery systems for small molecules, DNA, RNA and other biologic payloads. The first of these are now in the clinic.

    • Megan Cully
    News
  • News in Brief

  • Biobusiness Briefs

  • An Audience With

    • With multiple COVID-19 vaccines approaching the finish line, and dozens of COVID-19 drugs in development, more eyes are on the European Medicines Agency (EMA)’s decisions than ever before. Emer Cooke, who started as Executive Director of the EMA in November, is ready. Cooke, a pharmacist by training, has more than 30 years’ experience in pharmaceutical regulation. During this time, she has seen the system transform: the typewriters and carbon copy are gone, replaced by unprecedented volumes of data and complexity. With prior roles that have included oversight of the regulation of medical products at the World Health Organization, Head of Inspections at the EMA and Head of International Affairs at the EMA, she is prepared for the multidisciplinary nature of the challenges ahead. She spoke with Asher Mullard about the speed of progress with COVID-19 vaccines, the potential longer-term impacts of the pandemic on regulatory affairs and her goals for the EMA once the world returns to business as usual.

      • Asher Mullard
      An Audience With
  • From the Analyst's Couch

Top of page ⤴

Research Highlights

Top of page ⤴

Reviews

  • FOXO proteins are transcription factors that regulate responses to stress stimuli to maintain cellular homeostasis. The deregulation of FOXO protein functions plays a role in cardiovascular disease, cancer, diabetes and neurological diseases. This Review summarizes the biology of FOXO proteins and their functions in disease and longevity and discusses the pharmacological approaches to develop FOXO-targeting therapeutics.

    • Giampaolo Calissi
    • Eric W.-F. Lam
    • Wolfgang Link
    Review Article
  • Unmet medical needs in the treatment of autoimmune and inflammatory diseases still exist. This Review discusses the activity of kinases that regulate production of inflammatory mediators and the recent advances in developing inhibitors to target such kinases.

    • Ali A. Zarrin
    • Katherine Bao
    • Domagoj Vucic
    Review Article
Top of page ⤴

Perspectives

  • Academic research has a key role in identifying new drug targets, but to lead to new drugs this research must progress to testing drug candidates in clinical trials, which are typically conducted by industry. This Perspective presents a framework to support academic scientists and funders in prioritizing target assessment activities and in defining a critical path to reach scientific goals as well as goals related to licensing, partnering with industry or initiating clinical trials.

    • Christoph H. Emmerich
    • Lorena Martinez Gamboa
    • Michael J. Parnham
    Perspective
Top of page ⤴

Amendments & Corrections

Top of page ⤴

Search

Quick links